Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (321-330 of 418) with videos related to

Pageof 42
Sort By:
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
Scientific Reports|March 10, 2017
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitorsYunching Chen, Ya-Chi Liu, Yun-Chieh Sung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK InhibitorsAndrea Aloia, Daniela Müllhaupt, Christophe D Chabbert, et al.
Annals of Surgical Oncology|February 18, 2014
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patientsCharles M Balch, John F Thompson, Jeffrey E Gershenwald, et al.
JCO Precision Oncology|August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and PFilip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Multiple Gastrointestinal Polyps in Patients Treated with BRAF InhibitorsRavi K Amaravadi, Kathryn E Hamilton, Xiaohong Ma, et al.
Cancer Discovery|June 6, 2020
Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2Gretchen M Alicea, Vito W Rebecca, Aaron R Goldman, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
Pageof 42

Showing results (321-330 of 418) with videos related to

Sort By:
Pageof 42
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
Scientific Reports|March 10, 2017
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitorsYunching Chen, Ya-Chi Liu, Yun-Chieh Sung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol WYoung K Chae, Fangxin Hong, Christos Vaklavas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK InhibitorsAndrea Aloia, Daniela Müllhaupt, Christophe D Chabbert, et al.
Annals of Surgical Oncology|February 18, 2014
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patientsCharles M Balch, John F Thompson, Jeffrey E Gershenwald, et al.
JCO Precision Oncology|August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and PFilip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Multiple Gastrointestinal Polyps in Patients Treated with BRAF InhibitorsRavi K Amaravadi, Kathryn E Hamilton, Xiaohong Ma, et al.
Cancer Discovery|June 6, 2020
Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2Gretchen M Alicea, Vito W Rebecca, Aaron R Goldman, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
Pageof 42